Overview

Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients

Status:
Completed
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
The study is designed to approve non-inferior efficacy and safety of Insulin RinGlar® compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients.
Phase:
Phase 3
Details
Lead Sponsor:
Geropharm
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc
Pharmaceutical Solutions